GV co-leads $27.1M Series A in Oxford Uni life sciences spinout Vaccitech

Jan 15, 2018 · techcrunch.com

Isis vaccitech by john cairns 20 4 16 78 copy

Leaning on its in-house life sciences expertise GV has backed another biotech startup in the UK, co-leading a £20 million ($27.1M) Series A in Oxford University spinout Vaccitech, which is developing a universal flu vaccine.

Sequoia China, another new investor, is also co-leading the round, along with existing backer Oxford Sciences Innovation (OSI) — which operates a fund that invests in high tech spinouts from Oxford University (and counts GV as one of its backers). Neptune Ventures also participated in Vaccitech’s financing.

The company says the new funding will be used to expand its business, develop its lab structure, and push its influenza and prostate cancer programs through Phase II clinical trials by the end of 2019, as well as moving three other programs into the clinic.

It’s working on six products in all — based on inducing cellular immune responses using non-replicating viral vectors for treatment or prophylaxis against diseases at various stages.

As well as a universal influenza vaccine, Vaccitech has a prostate cancer therapeutic in development; a Middle East Respiratory Syndrome (MERS) prophylactic; a Human Papillomavirus (HPV) therapeutic; a Hepatitis B (HBV) therapeutic; and another infectious disease asset which it says is in late preclinical development.

Read Complete Article

@santanderuk, @TheFCA, @tinkoff_team, @ExoInvesting, @Topdanmark, @DirectLine_UK, @landg_uk, @AIGinsurance,… https://t.co/Ip5Pjc8y4E

I’ll be on the @ITV Late Debate tonight with @SimonHarrisITV - watch from 10.45pm.

"There's all kinds of #gadgets & #tech that people are showcasing, and these things all come together - it's never… https://t.co/S8fjSxVUAU

China’s fourth-quarter GDP: five things to watch https://t.co/wuVpJnevJg

Star Trek: The technology won, but Roddenberry's visionary society lost https://t.co/LFjTpa1ZkI by @jperlow